Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Asset Writedowns and Impairment (2016 - 2025)

Sanara MedTech (SMTI) has disclosed Asset Writedowns and Impairment for 11 consecutive years, with $165199.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Asset Writedowns and Impairment rose 120.27% year-over-year to $165199.0, compared with a TTM value of $727420.0 through Sep 2025, up 71.69%, and an annual FY2024 reading of $624448.0, up 53.5% over the prior year.
  • Asset Writedowns and Impairment was $165199.0 for Q3 2025 at Sanara MedTech, up from $115000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $412192.0 in Q4 2022 and bottomed at $7312.0 in Q1 2021.
  • Average Asset Writedowns and Impairment over 5 years is $113530.4, with a median of $87898.0 recorded in 2022.
  • The sharpest move saw Asset Writedowns and Impairment tumbled 63.65% in 2021, then skyrocketed 412.24% in 2023.
  • Year by year, Asset Writedowns and Impairment stood at $200290.0 in 2021, then skyrocketed by 105.8% to $412192.0 in 2022, then crashed by 53.24% to $192751.0 in 2023, then soared by 39.14% to $268187.0 in 2024, then crashed by 38.4% to $165199.0 in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for SMTI at $165199.0 in Q3 2025, $115000.0 in Q2 2025, and $179034.0 in Q1 2025.